- December 2, 2013
- November 27, 2013
Jérôme Tiollier, Executive Vice President and Chief Development Officer, was at the Agora of Presidents on ACTIONARIA (November 22, 2013, Paris, France)
- November 23, 2013
Innate financing confirms importance of US to European biotechs
Innate Pharma this week became the latest European drug developer to turn to the US to seek investor support. The French immuno-oncology company raised €20.3m ($27.3m) in a private placement directed exclusively at investors across the Atlantic, sending its Paris-listed shares to a six-year high.
- November 21, 2013
Le 21 novembre, la levée de fonds de 20 millions d'euros d'Innate Pharma aux USA a été le sujet abordé par Hervé Brailly, Président du Directoire d'Innate Pharma interviewé par Sébastien Couasnon, dans Intégrale Bourse, sur BFM Business.
- October 28, 2013
- October 17, 2013
On October 15, 2013, Innate Pharma (IPH.PA) presented a new proprietary technology for generating antibody-drug conjugates (ADCs) at the World ADC Summit in San Francisco.
The technology represents an opportunity for Innate to expand its portfolio of developmental candidatesor form strategic partnerships with leading companies.
- September 30, 2013
With very promising clinical results in oncology, immunotherapy is back at the front of the international scene. In France projects come out on the academic and industrial side.
In France several companies of biotechnology are already positioned in immunotherapy with, at the head, Transgene and Innate Pharma, whose results of products under development are expected impatiently
Article Monthly Pharmaceutiques September 2013 - Anne Pezet
- September 20, 2013
- September 13, 2013
- July 2, 2013